These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 19594323)

  • 21. Direct and indirect costs attributable to osteoarthritis in active subjects.
    Rabenda V; Manette C; Lemmens R; Mariani AM; Struvay N; Reginster JY
    J Rheumatol; 2006 Jun; 33(6):1152-8. PubMed ID: 16755664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of psoriasis on health care costs and patient work loss.
    Fowler JF; Duh MS; Rovba L; Buteau S; Pinheiro L; Lobo F; Sung J; Doyle JJ; Swensen A; Mallett DA; Kosicki G
    J Am Acad Dermatol; 2008 Nov; 59(5):772-80. PubMed ID: 19119095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of neutropenic fever in patients receiving first-line adjuvant chemotherapy for epithelial ovarian cancer.
    Sharma S; Rezai K; Driscoll D; Odunsi K; Lele S
    Gynecol Oncol; 2006 Oct; 103(1):181-5. PubMed ID: 16574203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections.
    Safdar A; Hanna HA; Boktour M; Kontoyiannis DP; Hachem R; Lichtiger B; Freireich EJ; Raad II
    Cancer; 2004 Dec; 101(12):2859-65. PubMed ID: 15529309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
    Lyman GH; Delgado DJ
    Cancer; 2003 Dec; 98(11):2402-9. PubMed ID: 14635075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database.
    Joish VN; Donaldson G; Stockdale W; Oderda GM; Crawley J; Sasane R; Joshua-Gotlib S; Brixner DI
    Curr Med Res Opin; 2005 Apr; 21(4):535-44. PubMed ID: 15899102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia.
    Donohue R
    Oncol Nurs Forum; 2006 Nov; 33(2):347-52. PubMed ID: 16518450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Healthcare utilization and costs of patients with rosacea in an insured population.
    Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
    J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin.
    Chamilos G; Bamias A; Efstathiou E; Zorzou PM; Kastritis E; Kostis E; Papadimitriou C; Dimopoulos MA
    Cancer; 2005 Jun; 103(12):2629-35. PubMed ID: 15856427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of a Protective Environment implementation for cancer patients with chemotherapy-induced neutropenia on fever and mortality incidence.
    Stoll P; Silla LM; Cola CM; Splitt BI; Moreira LB
    Am J Infect Control; 2013 Apr; 41(4):357-9. PubMed ID: 23102987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Costs Associated with Productivity Loss Among U.S. Patients Newly Diagnosed with Multiple Myeloma Receiving Oral Versus Injectable Chemotherapy.
    Merola D; Yong C; Noga SJ; Shermock KM
    J Manag Care Spec Pharm; 2018 Oct; 24(10):1019-1026. PubMed ID: 30247101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Systematic Review of the Effect of Cancer Treatment on Work Productivity of Patients and Caregivers.
    Kamal KM; Covvey JR; Dashputre A; Ghosh S; Shah S; Bhosle M; Zacker C
    J Manag Care Spec Pharm; 2017 Feb; 23(2):136-162. PubMed ID: 28125370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Productivity loss and indirect costs associated with cardiovascular events and related clinical procedures.
    Song X; Quek RG; Gandra SR; Cappell KA; Fowler R; Cong Z
    BMC Health Serv Res; 2015 Jun; 15():245. PubMed ID: 26104784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.
    Hirsch BR; Lyman GH
    Pharmacoeconomics; 2012 Jun; 30(6):497-511. PubMed ID: 22540394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of neutropenic complications on short-term disability in patients with cancer receiving chemotherapy.
    Song X; Fowler R; Ruiz K; Hurley D; Barron RL
    J Med Econ; 2009 Jun; 12(2):154-63. PubMed ID: 19594323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Costs of asthma among US working adults.
    Shenolikar R; Song X; Anderson JA; Chu BC; Cantrell CR
    Am J Manag Care; 2011 Jun; 17(6):409-16. PubMed ID: 21756011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients.
    Bennett CL; Calhoun EA
    Oncologist; 2007 Apr; 12(4):478-83. PubMed ID: 17470690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000.
    Chang S; Long SR; Kutikova L; Bowman L; Finley D; Crown WH; Bennett CL
    J Clin Oncol; 2004 Sep; 22(17):3524-30. PubMed ID: 15337801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutropenic complications in advanced-stage non-Hodgkin's lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF).
    Bobey N; Woodman RC
    Clin Invest Med; 1998 Apr; 21(2):63-70. PubMed ID: 9562926
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.